Articles tagged "Liver transplantation"

2019 American Transplant Congress
Preemptive Therapy is Cost Effective When Compared to Prophylaxis in Cytomegalovirus Donor Positive – Recipient Negative Liver Transplant Recipients
M. M. Wagener¹, D. J. Winston², R. R. Razonable³, G. M. Lyon III⁴, F. P. Silveira⁵, A. P. Limaye⁶, N. Singh¹
¹ID, U Pittsburgh and VAPHS, Pittsburgh, PA, ²ID, UCLA, Los Angeles, CA, ³ID, Mayo Clinic, Rochester, MN, ⁴ID, Emory, Atlanta, GA, ⁵ID, U Pittsburgh, Pittsburgh, PA, ⁶ID, U Washington, Seattle, WA
*Purpose: To compare the cost effectiveness of preemptive therapy (PET) vs prophylaxis for the prevention of cytomegalovirus (CMV) in high-risk donor seropositive/recipient seronegative (D+R-) liver…
2019 American Transplant Congress
No Gains In Long-term Survival Of Pediatric Patients After Liver Transplantation – A Three Decade Analysis
S. Bakhtiyar, A. Rana, S. Ahmed, H. Naseem, M. Kueht, N. T. Galvan, R. T. Cotton, C. A. O'Mahony, J. A. Goss
Baylor College of Medicine, Houston, TX
*Purpose: The aim of this study was to assess improvements in long-term survival of pediatric patients after liver transplantation, by analyzing outcomes in transplant recipients…
2019 American Transplant Congress
Treatment Modality Affects Outcomes of Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A US Multicenter Analysis of 2786 Patients
P. Tabrizian¹, K. J. Halazun², M. L. Holzner¹, N. Mehta³, F. Y. Yao³, J. Roberts³, J. C. Emond⁴, B. Samstein², R. S. Brown⁴, S. Florman¹, M. E. Schwartz¹, M. M. Doyle⁵, W. C. Chapman⁵, M. Najjar⁴, R. W. Busuttil⁶, V. G. Agopian⁶
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Transplant, Weill Cornell Medicine, New York, NY, ³Transplant, University of California San Francisco, San Francisco, CA, ⁴Transplant, Columbia University Medical Center, New York, NY, ⁵Transplant, Washington University School of Medicine, St Louis, MO, ⁶Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) has a poor prognosis. We evaluated the impact of treatment modalities on post-recurrence survival.*Methods: Adult patients…
2019 American Transplant Congress
Renal Safety Of Entecavir And Tenofovir With Hepatitis B Immunoglobulin In Liver Transplant Patients
D. Kim¹, J. Lee¹, E. Kim¹, S. Kim¹, K. Ihn¹, D. Joo¹, K. Huh¹, B. Kim², M. Kim¹, S. Kim¹, Y. Kim¹, J. Lee¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…
2019 American Transplant Congress
Liver Transplantation for Acute Liver Failure: A 16 Year Experience with 214 Patients in the Post-MELD Era
R. McMillan, T. Ito, A. Aziz, A. Amin, A. Murray, J. DiNorcia III, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas
Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA
*Purpose: Liver transplantation (LT) remains the gold standard treatment for acute liver failure (ALF). Our center has previously reported outcomes in the pre-Model for End…
2019 American Transplant Congress
CD47 Blockade Promotes Hepatic Macrophage Polarization toward M1 during Normothermic Machine Perfusion of Discarded Human Livers
M. Xu¹, F. Zhou¹, S. Garcia-Aroz¹, B. Banan¹, W. Yang², G. Upadhya¹, K. Byrnes³, B. Wong¹, P. Manning⁴, Y. Lin¹, W. Chapman¹
¹Department of Surgery, Washington University School of Medicine, St. Louis, MO, ²Department of Genetics, Washington University School of Medicine, St. Louis, MO, ³Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ⁴Arch Oncology, St. Louis, MO, USA, St. Louis, MO
*Purpose: M1 macrophages have been shown to be able to phagocytize dead cells after ischemia-reperfusion injury (IRI). This study investigated the therapeutic effect of CD47…
2019 American Transplant Congress
Outcomes Following Open Inguinal Hernia Repair in Liver Transplant versus Cirrhotic Patients
N. Siegel, A. Kernodle, S. DiBrito, T. Ishaque, D. Segev, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Patients with cirrhosis are at an increased risk for post-operative complications after open inguinal hernia repair (OIHR). Conversely, liver transplant recipients (LTR) may have…
2019 American Transplant Congress
Five Years after Right Hepatectomy for Living Liver Donation: Donor State of Health
D. P. Hoyer, E. Malamutmann, G. Bagias, A. Oezcelik
General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany
*Purpose: Of utmost importance in living liver donation is the avoidance of postoperative complications and reduction of quality of life of the donor.*Methods: Inclusion criteria…
2019 American Transplant Congress
Use, Safety and Effectiveness of Hepatitis B Virus NAT-Positive Donor Livers in the Current Era
T. C. Lee, K. Safdar, L. K. Winer, M. C. Morris, A. Kassam, K. Luckett, R. Quillin III, K. Bari, N. Anwar, S. A. Shah
University of Cincinnati, Cincinnati, OH
*Purpose: The use of hepatitis B (HBV) core antibody positive (HBcAb+) donor allografts in liver transplantation (OLT) has become accepted practice; however, given limited data…
2019 American Transplant Congress
When to Transplant for Wilson’s Disease: A Review
M. Flanagan, S. Koohmaraie, M. Kueht, R. Cotton, C. O'Mahony, A. Rana, J. Goss, N. Galvan
Baylor College of Medicine, Houston, TX
*Purpose: Wilson’s disease (WD) is a rare genetic disorder of copper metabolism, which leads to the accumulation of copper in the body, causing damage to…